Belite Bio, Inc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 31.63 million compared to USD 12.65 million a year ago. Basic loss per share from continuing operations was USD 1.19 compared to USD 0.63 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.75 USD | +4.61% | +18.91% | -13.11% |
Apr. 26 | Belite Bio Unveils Plan to Offer 651,380 American Depository Shares | MT |
Mar. 22 | Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.11% | 1.16B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BLTE Stock
- News Belite Bio, Inc
- Belite Bio, Inc Reports Earnings Results for the Full Year Ended December 31, 2023